

Experiment Number: 99037 - 04

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Date Report Requested: 09/20/2016

Test Type: 90-DAY

alpha/beta Thujone mixture

Time Report Requested: 15:14:27

Route: GAVAGE

CAS Number: 76231-76-0

First Dose M/F: 08/14/02 / 08/15/02

Species/Strain: MICE/B6C3F1

Lab: SRI

NTP Study Number: C99037B
Lock Date: 04/04/2003
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 3.0.2.3_002
PWG Approval Date: NONE

Test Type: 90-DAY

alpha/beta Thujone mixture

Time Report Requested: 15:14:27

Route: GAVAGE

CAS Number: 76231-76-0

First Dose M/F: 08/14/02 / 08/15/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	6.25 MG/KG	12.5 MG/KG	25 MG/KG	50 MG/KG	75 MG/KG
------------------	---------	------------	------------	----------	----------	----------

Disposition Summary

Animals Initially In Study	10	10	10	10	10	10
Early Deaths						
Natural Death					9	10
Survivors						
Terminal Sacrifice	10	10	10	10	1	
Animals Examined Microscopically	10	10	10	10	10	10

ALIMENTARY SYSTEM

Esophagus	(10)	(0)	(0)	(10)	(9)	(10)
Gallbladder	(10)	(0)	(0)	(9)	(10)	(8)
Intestine Large, Cecum	(10)	(0)	(0)	(10)	(10)	(10)
Intestine Large, Colon	(10)	(0)	(0)	(10)	(10)	(10)
Intestine Large, Rectum	(10)	(0)	(0)	(10)	(10)	(10)
Intestine Small, Duodenum	(10)	(0)	(0)	(10)	(10)	(10)
Intestine Small, Ileum	(10)	(0)	(0)	(10)	(10)	(10)
Intestine Small, Jejunum	(10)	(0)	(0)	(10)	(9)	(9)
Liver	(10)	(0)	(0)	(10)	(10)	(10)
Depletion Glycogen	5 [1.2]			5 [1.6]	1 [2.0]	
Hematopoietic Cell Proliferation				2 [1.0]	1 [1.0]	2 [1.0]
Inflammation, Chronic Active	1 [1.0]					
Pancreas	(10)	(0)	(0)	(10)	(10)	(10)
Salivary Glands	(10)	(0)	(0)	(10)	(10)	(10)
Stomach, Forestomach	(10)	(0)	(0)	(10)	(10)	(10)
Stomach, Glandular	(10)	(0)	(0)	(10)	(10)	(10)
Cyst	3			2		
Edema				1 [2.0]		
Infiltration Cellular, Eosinophil				1 [2.0]		

CARDIOVASCULAR SYSTEM

Heart	(10)	(0)	(0)	(10)	(10)	(10)
-------	------	-----	-----	------	------	------

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: 90-DAY

alpha/beta Thujone mixture

Time Report Requested: 15:14:27

Route: GAVAGE

CAS Number: 76231-76-0

First Dose M/F: 08/14/02 / 08/15/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	6.25 MG/KG	12.5 MG/KG	25 MG/KG	50 MG/KG	75 MG/KG
ENDOCRINE SYSTEM						
Adrenal Cortex	(10)	(10)	(10)	(10)	(10)	(10)
Adrenal Medulla	(10)	(10)	(10)	(10)	(10)	(10)
Parathyroid Gland	(10)	(0)	(0)	(10)	(10)	(9)
Cyst	1					
Pituitary Gland	(10)	(0)	(0)	(10)	(10)	(9)
Pars Distalis, Cyst					1	
Thyroid Gland	(10)	(0)	(0)	(10)	(10)	(10)
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM						
Epididymis	(10)	(0)	(0)	(10)	(10)	(10)
Preputial Gland	(10)	(0)	(0)	(10)	(10)	(10)
Inflammation, Chronic Active					1 [1.0]	
Prostate	(10)	(0)	(0)	(10)	(10)	(10)
Seminal Vesicle	(10)	(0)	(0)	(10)	(10)	(10)
Testes	(10)	(0)	(0)	(10)	(10)	(10)
HEMATOPOIETIC SYSTEM						
Bone Marrow	(10)	(0)	(0)	(10)	(10)	(10)
Lymph Node, Mandibular	(10)	(0)	(0)	(10)	(9)	(10)
Lymph Node, Mesenteric	(9)	(0)	(0)	(10)	(10)	(9)
Spleen	(10)	(0)	(0)	(10)	(10)	(10)
Hyperplasia, Lymphoid	1 [2.0]					
Pigmentation, Hemosiderin, Focal	1 [1.0]					
Thymus	(10)	(0)	(0)	(10)	(10)	(10)

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: 90-DAY

alpha/beta Thujone mixture

Time Report Requested: 15:14:27

Route: GAVAGE

CAS Number: 76231-76-0

First Dose M/F: 08/14/02 / 08/15/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	6.25 MG/KG	12.5 MG/KG	25 MG/KG	50 MG/KG	75 MG/KG
INTEGUMENTARY SYSTEM						
Skin	(10)	(0)	(0)	(10)	(10)	(10)
MUSCULOSKELETAL SYSTEM						
Bone	(10)	(0)	(0)	(10)	(10)	(10)
Skeletal Muscle	(10)	(0)	(0)	(2)	(10)	(10)
NERVOUS SYSTEM						
Brain	(10)	(10)	(10)	(10)	(10)	(10)
Peripheral Nerve	(10)	(0)	(0)	(5)	(10)	(10)
Spinal Cord	(10)	(0)	(0)	(4)	(10)	(10)
Congestion					1 [2.0]	1 [2.0]
RESPIRATORY SYSTEM						
Lung	(10)	(0)	(0)	(10)	(10)	(10)
Congestion					1 [2.0]	5 [1.8]
Hemorrhage					5 [1.8]	1 [1.0]
Nose	(10)	(0)	(0)	(10)	(10)	(10)
Trachea	(10)	(0)	(0)	(10)	(10)	(10)
SPECIAL SENSES SYSTEM						
Eye	(10)	(0)	(0)	(10)	(10)	(10)
Inflammation, Acute				1 [1.0]		
Harderian Gland	(10)	(0)	(0)	(10)	(10)	(10)
Hyperplasia, Focal				1 [2.0]		
Inflammation, Acute	1 [2.0]			2 [1.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Experiment Number: 99037 - 04

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Date Report Requested: 09/20/2016

Test Type: 90-DAY

alpha/beta Thujone mixture

Time Report Requested: 15:14:27

Route: GAVAGE

CAS Number: 76231-76-0

First Dose M/F: 08/14/02 / 08/15/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	6.25 MG/KG	12.5 MG/KG	25 MG/KG	50 MG/KG	75 MG/KG
URINARY SYSTEM						
Kidney	(10)	(0)	(0)	(10)	(10)	(10)
Cyst				1		
Nephropathy	1 [1.0]			2 [1.0]	2 [1.0]	1 [1.0]
Renal Tubule, Mineralization						1 [1.0]
Urinary Bladder	(10)	(0)	(0)	(10)	(10)	(10)

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: 90-DAY

alpha/beta Thujone mixture

Time Report Requested: 15:14:27

Route: GAVAGE

CAS Number: 76231-76-0

First Dose M/F: 08/14/02 / 08/15/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	6.25 MG/KG	12.5 MG/KG	25 MG/KG	50 MG/KG	75 MG/KG
--------------------	---------	------------	------------	----------	----------	----------

Disposition Summary

Animals Initially In Study	10	10	10	10	10	10
Early Deaths						
Natural Death					7	10
Survivors						
Terminal Sacrifice	10	10	10	10	3	
Animals Examined Microscopically	10	10	10	10	10	10

ALIMENTARY SYSTEM

Esophagus	(10)	(0)	(0)	(10)	(10)	(10)
Gallbladder	(10)	(0)	(0)	(10)	(10)	(10)
Intestine Large, Cecum	(10)	(0)	(0)	(10)	(10)	(10)
Intestine Large, Colon	(10)	(0)	(0)	(10)	(10)	(10)
Intestine Large, Rectum	(10)	(0)	(0)	(10)	(10)	(10)
Intestine Small, Duodenum	(10)	(0)	(0)	(10)	(9)	(10)
Intestine Small, Ileum	(10)	(0)	(0)	(10)	(10)	(10)
Intestine Small, Jejunum	(10)	(0)	(0)	(10)	(8)	(10)
Liver	(10)	(0)	(0)	(10)	(10)	(10)
Hematopoietic Cell Proliferation	3 [1.0]			3 [1.0]	4 [1.0]	2 [1.0]
Hepatodiaphragmatic Nodule						1
Pancreas	(10)	(0)	(0)	(10)	(10)	(10)
Acinus, Atrophy, Focal	1 [2.0]					
Salivary Glands	(10)	(0)	(0)	(10)	(10)	(10)
Stomach, Forestomach	(10)	(0)	(0)	(10)	(10)	(10)
Stomach, Glandular	(10)	(0)	(0)	(10)	(10)	(10)
Cyst	2					
Mineralization	1 [1.0]					

CARDIOVASCULAR SYSTEM

Heart	(10)	(0)	(0)	(10)	(10)	(10)
-------	------	-----	-----	------	------	------

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: 90-DAY

alpha/beta Thujone mixture

Time Report Requested: 15:14:27

Route: GAVAGE

CAS Number: 76231-76-0

First Dose M/F: 08/14/02 / 08/15/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	6.25 MG/KG	12.5 MG/KG	25 MG/KG	50 MG/KG	75 MG/KG
ENDOCRINE SYSTEM						
Adrenal Cortex	(10)	(10)	(10)	(10)	(10)	(10)
Accessory Adrenal Cortical Nodule					1 [2.0]	
Adrenal Medulla	(10)	(0)	(0)	(10)	(10)	(10)
Parathyroid Gland	(10)	(0)	(0)	(10)	(10)	(9)
Pituitary Gland	(10)	(0)	(0)	(10)	(10)	(10)
Thyroid Gland	(10)	(0)	(0)	(10)	(10)	(10)
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM						
Clitoral Gland	(9)	(0)	(0)	(10)	(10)	(10)
Ovary	(10)	(10)	(10)	(10)	(10)	(10)
Uterus	(10)	(10)	(10)	(10)	(10)	(10)
Dilatation			1 [1.0]			
Vagina	(10)	(10)	(10)	(10)	(10)	(10)
HEMATOPOIETIC SYSTEM						
Bone Marrow	(10)	(0)	(0)	(10)	(10)	(10)
Lymph Node, Mandibular	(9)	(0)	(0)	(10)	(10)	(10)
Lymph Node, Mesenteric	(10)	(0)	(0)	(10)	(10)	(9)
Spleen	(10)	(1)	(0)	(10)	(10)	(10)
Hematopoietic Cell Proliferation	1 [2.0]			1 [1.0]		
Hyperplasia, Lymphoid, Focal		1 [1.0]				
Thymus	(10)	(0)	(0)	(10)	(10)	(10)
INTEGUMENTARY SYSTEM						

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: 90-DAY

alpha/beta Thujone mixture

Time Report Requested: 15:14:27

Route: GAVAGE

CAS Number: 76231-76-0

First Dose M/F: 08/14/02 / 08/15/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	6.25 MG/KG	12.5 MG/KG	25 MG/KG	50 MG/KG	75 MG/KG
Mammary Gland	(10)	(0)	(0)	(10)	(10)	(10)
Skin	(10)	(0)	(0)	(10)	(10)	(10)
MUSCULOSKELETAL SYSTEM						
Bone	(10)	(0)	(0)	(10)	(10)	(10)
Skeletal Muscle	(10)	(0)	(0)	(5)	(10)	(10)
NERVOUS SYSTEM						
Brain	(10)	(10)	(10)	(10)	(10)	(10)
Inflammation, Acute					1 [1.0]	
Peripheral Nerve	(10)	(0)	(0)	(5)	(10)	(10)
Spinal Cord	(10)	(0)	(0)	(5)	(10)	(10)
RESPIRATORY SYSTEM						
Lung	(10)	(0)	(0)	(10)	(10)	(10)
Congestion					2 [1.5]	3 [1.7]
Hemorrhage					2 [1.0]	
Infiltration Cellular, Histiocyte, Focal				1 [2.0]		
Inflammation, Acute				1 [2.0]		
Nose	(10)	(0)	(0)	(10)	(10)	(10)
Trachea	(10)	(0)	(0)	(10)	(10)	(10)
SPECIAL SENSES SYSTEM						
Eye	(10)	(0)	(0)	(10)	(10)	(10)
Harderian Gland	(10)	(0)	(0)	(10)	(10)	(10)
Inflammation, Acute	1 [1.0]					
URINARY SYSTEM						

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Experiment Number: 99037 - 04

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Date Report Requested: 09/20/2016

Test Type: 90-DAY

alpha/beta Thujone mixture

Time Report Requested: 15:14:27

Route: GAVAGE

CAS Number: 76231-76-0

First Dose M/F: 08/14/02 / 08/15/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	6.25 MG/KG	12.5 MG/KG	25 MG/KG	50 MG/KG	75 MG/KG
Kidney	(10)	(0)	(0)	(10)	(10)	(10)
Casts Protein	3 [1.0]					
Nephropathy	1 [1.0]				1 [1.0]	
Urinary Bladder	(10)	(0)	(0)	(10)	(10)	(10)

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion
b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)